Table 1.
Currently approved subcutaneous long-acting formulations
| Brand name | International nonproprietary name | Strategy | Indication | Approval year |
|---|---|---|---|---|
| Ozempic | Semaglutide | Lipidation | Type 2 diabetes | 2017 |
| Xultophy 100/3.6 | Insulin degludec and liraglutide injection | Lipidation | Type 2 diabetes | 2016 |
| Tresiba | Insulin degludec | Lipidation | Type 1 and type 2 diabetes | 2015 |
| Tanzeum, Eperzan | Albiglutide | Albumin fusion | Type 2 diabetes | 2014 |
| Trulicity | Dulaglutide | Fc fusion | Type2 diabetes | 2014 |
| Saxenda | Liraglutide | Lipidation | Obesity | 2014 |
| Eloctate | Antihemophilic factor (recombinant) | Fc fusion | Hemophilia A | 2014 |
| Alprolix | Coagulation Factor IX (recombinant) | Fc fusion | Hemophilia B | 2014 |
| Eylea | Aflibercept | Fc fusion | Wet macular degeneration | 2011 |
| Nulojix | Belatacept | Fc fusion | Kidney transplant rejection | 2011 |
| Victoza | Liraglutide | Lipidation | Type 2 diabetes | 2010 |
| Arcalyst | Rilonacept | Fc fusion | Cryopyrin-associated periodic syndromes | 2008 |
| Nplate | Romiplostim | Fc fusion | Immune thrombocytopenic purpura | 2008 |
| Somatuline Depot | Lanreotide | Subcutaneous depot | Acromegaly | 2007 |
| Omnitrope | Somatropin (rDNA origin) | Subcutaneous depot | Growth hormone deficiency | 2006 |
| Orencia | Abatacept | Fc fusion | Rheumatoid arthritis | 2005 |
| Levemir | insuline detemir (rDNA origin) | Lipidation | Type 1 diabetes | 2005 |
| Bydureon | Exenatide | Subcutaneous depot | Type 2 diabetes | 2005 |
| Risperdal Consta | Risperidone | Subcutaneous depot | Schizophrenia and symptoms of bipolar disorder | 2003 |
| Enbrel | Etanercept | Fc fusion | Rheumatoid arthritis, psoriasis | 2002 |
| Nutropin AQ | Somatropin (rDNA origin) | Subcutaneous depot | Growth hormone deficiency | 1999 |
| Sandostatin Lar Depot | acetate | Subcutaneous depot | Acromegaly | 1998 |